Interactive Decision Support Tool on BsAb AE Management
Point-of-Care, Digital, Interactive Decision Support Tool (IDST) for the Prevention/Management of AEs During Treatment with BsAbs in MM

Released: January 06, 2025

Expiration: January 05, 2026

About This Tool & Disclaimer

Prevention and Management of AEs During Treatment with Bispecific Antibody Therapy in Multiple Myeloma

Clinical Care Options, LLC, is grateful to Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO; Melissa Pozotrigo, PharmD, BCOP; and Noopur Raje, MD, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in December 2024 and reflects the guidelines available at that time.

The goal of the tool is to educate healthcare professionals on making optimal management choices for managing bispecific antibody-related AEs based on current prescribing information instructions and expert recommendations.

A series of questions allow the participant to select individual patient characteristics that are necessary to consider when making AE management choices. These characteristics include which bispecific antibody therapy the patient is receiving, whether the AE occurred within the past 30 days, and what AE the patient is experiencing.

It should be noted that these are not exclusive characteristics when selecting optimal AE management for patients with R/R MM. Other considerations that are not included in this tool, such as the presence of various comorbidities and any concurrent medications, should also be considered when appropriate for making management decisions.

This tool assumes we have a “standard” patient with R/R MM but with no additional features or specific comorbidities that would affect AE management choice other than those described when entering the patient details. Based on the characteristics entered, the tool will display recommendations for that specific patient case.

For additional information on best practices in the management of patients with R/R MM, please see our program page titled, “Refining Therapeutic Approaches in R/R MM: Expert Guidance on Bispecific Antibody Therapy Optimization”.

This program is supported by an educational grant from Pfizer Inc., Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO: consultant/advisor/speaker: GlaxoSmithKline, Janssen, Sanofi

Melissa Pozotrigo, PharmD, BCOP, has no relevant financial relationships to disclose.

Noopur Raje, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Immuneel, Johnson & Johnson, Pfizer, Sanofi.

© 2024 Clinical Care Options, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Prevention and Management of AEs During Treatment with Bispecific Antibody Therapy in Multiple Myeloma” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate clinicians on making optimal management choices for bispecific antibody therapy-related AEs in patients with R/R MM. The information provided is based on the latest prescribing information instructions and expert guidance of Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO; Melissa Pozotrigo, PharmD, BCOP; and Noopur Raje, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the Clinical Care Options material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Prevention and Management of AEs During Treatment with Bispecific Antibody Therapy in Multiple Myeloma” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2024 Clinical Care Options, LLC. All rights reserved.

Program Content